<DOC>
	<DOCNO>NCT00671255</DOCNO>
	<brief_summary>This purpose study evaluate safety effectiveness Ramelteon , daily ( QD ) , elderly participant chronic insomnia .</brief_summary>
	<brief_title>Safety Efficacy Ramelteon Elderly Subjects With Chronic Insomnia</brief_title>
	<detailed_description>Insomnia characterize complaint initiate maintain sleep complaint nonrestorative non-refreshing sleep . Transient insomnia affect approximately one-third one-half US population , base result 2 survey representative sample adult US population conduct Gallup Organization respondent ask `` ever difficulty sleep . '' Based report `` regular '' `` frequent '' sleep difficulty , result study suggest approximately one-tenth US population experience chronic insomnia . The ideal treatment insomnia would reduce latency onset sleep increase total sleep time , without negative impact sleep architecture without safety concern next-day effect . Ramelteon selective melatonin-1 receptor agonist development Takeda Chemical Industries , Ltd. , treatment transient chronic insomnia treatment Circadian Rhythm Sleep Disorders . Ramelteon first candidate novel class drug base mechanism . Based non-clinical clinical study complete date , TAK-375 potential offer unique advantage relative approve hypnotic term pharmacological profile selectivity melatonin-1 receptor . This study design determine safety efficacy 35-day treatment chronic insomnia ramelteon . Participation study anticipate approximately 2 month .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Subject male postmenopausal female . Primary insomnia define Diagnostic Statistical Manual Mental Disorders , 4th Edition Revised least 3 month history daytime complaint ( ) associate disturbed sleep . Subjective sleep latency great equal 45 minute subjective total sleep time le equal 6.5 hour per night least 3 night week leadin period . Habitual bedtime 8:30 PM 12:00 AM . Body mass index 18 34 , inclusive . Exclusion Criteria Known hypersensitivity ramelteon related compound , include melatonin . Previously participate study involve ramelteon . Participated investigational study , and/or take investigational drug within 30 day five halflives prior first day singleblind study medication , whichever longer . Sleep schedule change require employment ( eg , shift worker ) within three month prior first day singleblind study medication , fly across great three time zone within seven day prior screen . Participated weight loss program substantially alter exercise routine within 30 day prior first day single blind study medication . Has ever history seizure , sleep apnea , chronic obstructive pulmonary disease , restless leg syndrome , schizophrenia , bipolar disorder , mental retardation , cognitive disorder . History psychiatric disorder within past 12 month . History drug addiction drug abuse within past 12 month . History alcohol abuse within past 12 month , define Diagnostic Statistical Manual Mental Disorders , 4th Edition Revised and/or regularly consume 4 alcoholic drink per day . Current significant neurological , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematologic metabolic disease , unless currently control stable protocolallowed medication . Uses tobacco product nightly awakening . Any clinically important abnormal finding determine medical history , physical examination , electrocardiogram , clinical laboratory test , determine investigator . Positive hepatitis panel . Any additional condition ( ) Investigator 's opinion would : affect sleepwake function prohibit subject complete study best interest subject . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication , include : Anxiolytics Hypnotics Antidepressants Anticonvulsants Sedating H1 antihistamine Systemic steroid Respiratory stimulant Decongestants Overthecounter prescription stimulant Overthecounter prescription diet aids Central nervous system active drug Narcotic analgesic All beta blocker Melatonin St. John 's Wort Kavakava Gingko biloba</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Chronic Insomnia</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Elderly</keyword>
</DOC>